2024
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration
Zengin Z, Henderson N, Park J, Ali A, Nguyen C, Hwang C, Barata P, Bilen M, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin V, Patel V, Schweizer M, Armstrong A, McKay R, Alva A, Dorff T. Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration. Prostate Cancer And Prostatic Diseases 2024, 28: 378-384. PMID: 38383885, PMCID: PMC12106060, DOI: 10.1038/s41391-024-00805-3.Peer-Reviewed Original ResearchAndrogen receptor-targeted agentsCastration-resistant prostate cancerAR alterationsAR amplificationAR mutationsProstate cancerGene alterationsClinical outcomesAssociated with longer time to progressionCastration-resistant prostate cancer patientsGenomic testingLonger time to progressionTime to progressionAdvanced prostate cancerReceptor-targeted agentsPSA responseMetastatic diseaseOverall survivalMulti-institutional collaborative effortTestosterone suppressionMedian ageTargeted agentsProspective studyTreatment outcomesTherapeutic strategies
2023
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Antonarakis E, Subudhi S, Pieczonka C, Karsh L, Quinn D, Hafron J, Wilfehrt H, Harmon M, Sheikh N, Shore N, Petrylak D. Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. Clinical Cancer Research 2023, 29: 2426-2434. PMID: 37058234, PMCID: PMC10320463, DOI: 10.1158/1078-0432.ccr-22-3832.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerAndrogen receptor-targeted agentsMedian overall survivalCastration-resistant prostate cancerOverall survivalNational Death IndexConcurrent administrationProstate cancerAntigen-presenting cell activationCurrent prescribing informationNew safety signalsKaplan-Meier methodologyLong-term outcomesConfidence intervalsReceptor-targeted agentsProstatic acid phosphataseAbiraterone acetateFirst infusionDeath IndexPrescribing informationHumoral responseSubsequent infusionSequential administrationSafety signalsImmune response
2018
Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting
Oh W, Cheng W, Miao R, Vekeman F, Gauthier-Loiselle M, Duh M, Drea E, Szatrowski T. Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting. Urologic Oncology Seminars And Original Investigations 2018, 36: 500.e1-500.e9. PMID: 30201382, DOI: 10.1016/j.urolonc.2018.08.002.Peer-Reviewed Original ResearchMeSH KeywordsAgedAndrogen AntagonistsAndrostenesAntineoplastic Combined Chemotherapy ProtocolsBenzamidesDisease ProgressionDisease-Free SurvivalDocetaxelHumansKaplan-Meier EstimateMaleMiddle AgedNitrilesPhenylthiohydantoinProportional Hazards ModelsProstatic Neoplasms, Castration-ResistantRetrospective StudiesTaxoidsTreatment OutcomeConceptsSecond-line chemotherapyProstate-specific antigenMetastatic castration-resistant prostate cancerAndrogen receptor-targeted agentsCastration-resistant prostate cancerReceptor-targeted agentsOverall survivalEarly progressionProstate cancerOpioid usePoor prognosisEastern Cooperative Oncology Group performance scoreSecond-line therapy initiationTime to PSA progressionUS community oncology settingLactate dehydrogenaseRetrospective observational studyUS community settingsGroup performance scoreCommunity oncology settingAlkaline phosphatasePSA progressionClinical responsePrognostic featuresTherapy initiation
2017
Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) chemotherapy (CT) vs alternative androgen receptor-targeted agents (ARTA) after lack of response to first-line (1L) ARTA in US community oncology practices.
Oh W, Cheng W, Miao R, Vekeman F, Gauthier-Loiselle M, Duh M, Drea E, Szatrowski T. Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) chemotherapy (CT) vs alternative androgen receptor-targeted agents (ARTA) after lack of response to first-line (1L) ARTA in US community oncology practices. Journal Of Clinical Oncology 2017, 35: 214-214. DOI: 10.1200/jco.2017.35.6_suppl.214.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerProstate-specific antigenOverall survivalOpioid useAndrogen receptor-targeted agentsPSA responseUS community oncology settingCastration-resistant prostate cancerResponse to first-lineLactate dehydrogenaseIncreased opioid useCox proportional hazards regression modelsECOG performance scoreReceptor-targeted agentsUS community oncology practicesNon-statistically significant trendProportional hazards regression modelsAlkaline phosphataseHazards regression modelsCommunity oncology settingImproved OSSecond-lineCommunity oncology practicesPrognostic featuresProstate cancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply